Results 71 to 80 of about 1,795 (145)

Clinical Evidence and Safety Profile of Emicizumab for the Management of Children with Hemophilia A

Drug Design, Development and Therapy, 2020
Sandra Le Quellec1,2 1Unité d’hémostase Clinique – Hôpital Cardiologique Louis Pradel – Hospices Civils de Lyon, Lyon, France; 2Service d’hématologie biologique, Groupement Hospitalier Est &ndash ...
Le Quellec S
doaj  

PO86 | Emicizumab in patients with moderate hemophilia A and severe bleeding phenotype: single-center real-world experience

Bleeding, Thrombosis and Vascular Biology
Background and Aims: The role of prophylaxis in moderate hemophilia A (HA) patients is less clear than in severe HA, given their variable bleeding phenotype.
doaj   +1 more source

CO31 | Immune system profiling in FVIII-treated and emicizumab-treated pediatric HA patients

Bleeding, Thrombosis and Vascular Biology
Background: Prophylactic treatments to prevent bleeding are considered the standard therapy in Hemophilia A (HA) and inhibitor formation is the main complication of FVIII infusion.
doaj   +1 more source

Myeloid Cell Function and Cytokine Profiles in Paediatric Haemophilia A: Insights From FVIII and Emicizumab Prophylaxis. [PDF]

J Cell Mol Med
Cottonaro A, Akula S, Pollio B, Ricca I, Martini T, Albiani R, Giacchello JA, Sciancalepore P, Santi R, Follenzi A, Merlin S.   +10 more
europepmc   +1 more source

Development of a novel hemophilia A mouse model to study emicizumab and factor VIII inhibitor risk. [PDF]

Blood Adv
Chou SC, Chang YT, Chen LF, Tsai CH, Cheng CY, Sun CP, Tao MH, Hong CL, Wu HL, Lin SW.   +9 more
europepmc   +1 more source

Transition to Emicizumab from standard-dose FVIII prophylaxis in young children with hemophilia A: a real-world study. [PDF]

Thromb J
Ye J, Huang K.
europepmc   +1 more source

Intrinsic activated thrombin generation for treatment efficacy and monitoring of octocog alfa and emicizumab in severe hemophilia A. [PDF]

Res Pract Thromb Haemost
Urlings EH, Heubel-Moenen FCJI, van Oerle R, Hellenbrand DLS, van der Meijden PEJ, Hackeng TM, Cate HT, Nagy M, Henskens YMC, Spronk HMH.   +9 more
europepmc   +1 more source

In Vitro Study of the Role of Factor IX in Treatment of Breakthrough Bleeds in Patients with Hemophilia A and Inhibitors Receiving Emicizumab. [PDF]

TH Open
Janbain M, Josset L, Leuci A, Zakharia K, Ksayer R, Nougier C, Leissinger C, Dargaud Y.   +7 more
europepmc   +1 more source

Procoagulant Effect of FIX Concentrates and Bypass Agents in Combination with Emicizumab and Impact of FVIII Inhibitors. [PDF]

Biomedicines
Arias-Salgado EG, Álvarez Román MT, Dos Santos Ortas A, Fernandéz-Bello I, Monzón Manzano E, Acuña P, Martín Salces M, Rivas Pollmar MI, García Barcenilla S, Butta NV, Jimenéz-Yuste V.   +10 more
europepmc   +1 more source

Emicizumab prophylaxis beyond clinical trials: a multicenter, prospective real-world study of pediatric hemophilia patients with and without inhibitors. [PDF]

Eur J Pediatr
Sherief LM, Elagamy O, Darwish A, Soliman NK, Elgendy MR, Nazim A, Sobhi A.   +6 more
europepmc   +1 more source